494 related articles for article (PubMed ID: 23574329)
1. Human mesenchymal stem cells suppress donor CD4(+) T cell proliferation and reduce pathology in a humanized mouse model of acute graft-versus-host disease.
Tobin LM; Healy ME; English K; Mahon BP
Clin Exp Immunol; 2013 May; 172(2):333-48. PubMed ID: 23574329
[TBL] [Abstract][Full Text] [Related]
2. Human peripheral blood CD4 T cell-engrafted non-obese diabetic-scid IL2rγ(null) H2-Ab1 (tm1Gru) Tg (human leucocyte antigen D-related 4) mice: a mouse model of human allogeneic graft-versus-host disease.
Covassin L; Laning J; Abdi R; Langevin DL; Phillips NE; Shultz LD; Brehm MA
Clin Exp Immunol; 2011 Nov; 166(2):269-80. PubMed ID: 21985373
[TBL] [Abstract][Full Text] [Related]
3. The P2X7 receptor antagonist Brilliant Blue G reduces serum human interferon-γ in a humanized mouse model of graft-versus-host disease.
Geraghty NJ; Belfiore L; Ly D; Adhikary SR; Fuller SJ; Varikatt W; Sanderson-Smith ML; Sluyter V; Alexander SI; Sluyter R; Watson D
Clin Exp Immunol; 2017 Oct; 190(1):79-95. PubMed ID: 28665482
[TBL] [Abstract][Full Text] [Related]
4. Extracellular Vesicles Released from Human Umbilical Cord-Derived Mesenchymal Stromal Cells Prevent Life-Threatening Acute Graft-Versus-Host Disease in a Mouse Model of Allogeneic Hematopoietic Stem Cell Transplantation.
Wang L; Gu Z; Zhao X; Yang N; Wang F; Deng A; Zhao S; Luo L; Wei H; Guan L; Gao Z; Li Y; Wang L; Liu D; Gao C
Stem Cells Dev; 2016 Dec; 25(24):1874-1883. PubMed ID: 27649744
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model.
Grégoire C; Ritacco C; Hannon M; Seidel L; Delens L; Belle L; Dubois S; Vériter S; Lechanteur C; Briquet A; Servais S; Ehx G; Beguin Y; Baron F
Front Immunol; 2019; 10():619. PubMed ID: 31001253
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
Tian Y; Deng YB; Huang YJ; Wang Y
Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
[TBL] [Abstract][Full Text] [Related]
7. A novel study on the immunomodulatory effect of umbilical cord derived mesenchymal stem cells pretreated with traditional Chinese medicine Asarinin.
He H; Yang T; Li F; Zhang L; Ling X
Int Immunopharmacol; 2021 Nov; 100():108054. PubMed ID: 34492537
[TBL] [Abstract][Full Text] [Related]
8. Increased splenic human CD4
Geraghty NJ; Belfiore L; Adhikary SR; Alexander SI; Sluyter R; Watson D
Transpl Immunol; 2019 Jun; 54():38-46. PubMed ID: 30743002
[TBL] [Abstract][Full Text] [Related]
9. Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rγnull mice display a T-effector memory phenotype.
Ali N; Flutter B; Sanchez Rodriguez R; Sharif-Paghaleh E; Barber LD; Lombardi G; Nestle FO
PLoS One; 2012; 7(8):e44219. PubMed ID: 22937164
[TBL] [Abstract][Full Text] [Related]
10. Attenuation of graft-versus-host-disease in NOD scid IL-2Rγ(-/-) (NSG) mice by ex vivo modulation of human CD4(+) T cells.
Hilger N; Glaser J; Müller C; Halbich C; Müller A; Schwertassek U; Lehmann J; Ruschpler P; Lange F; Boldt A; Stahl L; Sack U; Oelkrug C; Emmrich F; Fricke S
Cytometry A; 2016 Sep; 89(9):803-15. PubMed ID: 27560708
[TBL] [Abstract][Full Text] [Related]
11. Human T cells depend on functional calcineurin, tumour necrosis factor-α and CD80/CD86 for expansion and activation in mice.
Søndergaard H; Kvist PH; Haase C
Clin Exp Immunol; 2013 May; 172(2):300-10. PubMed ID: 23574326
[TBL] [Abstract][Full Text] [Related]
12. Enhanced alleviation of aGVHD by TGF-β1-modified mesenchymal stem cells in mice through shifting MΦ into M2 phenotype and promoting the differentiation of Treg cells.
Wu R; Liu C; Deng X; Chen L; Hao S; Ma L
J Cell Mol Med; 2020 Jan; 24(2):1684-1699. PubMed ID: 31782262
[TBL] [Abstract][Full Text] [Related]
13. Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults.
Gonzalo-Daganzo R; Regidor C; Martín-Donaire T; Rico MA; Bautista G; Krsnik I; Forés R; Ojeda E; Sanjuán I; García-Marco JA; Navarro B; Gil S; Sánchez R; Panadero N; Gutiérrez Y; García-Berciano M; Pérez N; Millán I; Cabrera R; Fernández MN
Cytotherapy; 2009; 11(3):278-88. PubMed ID: 19308773
[TBL] [Abstract][Full Text] [Related]
14. Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease.
Trujillo-Ocampo A; Cho HW; Herrmann AC; Ruiz-Vazquez W; Thornton AB; He H; Li D; Qazilbash MA; Ma Q; Porcelli SA; Shpall EJ; Molldrem J; Im JS
Cytotherapy; 2018 Aug; 20(8):1089-1101. PubMed ID: 30076070
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Keklik M; Deveci B; Celik S; Deniz K; Gonen ZB; Zararsiz G; Saba R; Akyol G; Ozkul Y; Kaynar L; Keklik E; Unal A; Cetin M; Jones OY
Ann Hematol; 2023 Jun; 102(6):1537-1547. PubMed ID: 37067556
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation.
Zhao K; Lou R; Huang F; Peng Y; Jiang Z; Huang K; Wu X; Zhang Y; Fan Z; Zhou H; Liu C; Xiao Y; Sun J; Li Y; Xiang P; Liu Q
Biol Blood Marrow Transplant; 2015 Jan; 21(1):97-104. PubMed ID: 25300866
[TBL] [Abstract][Full Text] [Related]
17. Effective treatment against severe graft-versus-host disease with allele-specific anti-HLA monoclonal antibody in a humanized mouse model.
Nakauchi Y; Yamazaki S; Napier SC; Usui J; Ota Y; Takahashi S; Watanabe N; Nakauchi H
Exp Hematol; 2015 Feb; 43(2):79-88.e1-4. PubMed ID: 25448490
[TBL] [Abstract][Full Text] [Related]
18. γδ T Cells May Aggravate Acute Graft-Versus-Host Disease Through CXCR4 Signaling After Allogeneic Hematopoietic Transplantation.
Wu N; Liu R; Liang S; Gao H; Xu LP; Zhang XH; Liu J; Huang XJ
Front Immunol; 2021; 12():687961. PubMed ID: 34335589
[TBL] [Abstract][Full Text] [Related]
19. Humanized Chronic Graft-versus-Host Disease in NOD-SCID il2rγ-/- (NSG) Mice with G-CSF-Mobilized Peripheral Blood Mononuclear Cells following Cyclophosphamide and Total Body Irradiation.
Fujii H; Luo ZJ; Kim HJ; Newbigging S; Gassas A; Keating A; Egeler RM
PLoS One; 2015; 10(7):e0133216. PubMed ID: 26176698
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal Stromal Cell (MSC)-Derived Combination of CXCL5 and Anti-CCL24 Is Synergistic and Superior to MSC and Cyclosporine for the Treatment of Graft-versus-Host Disease.
Fan X; Guo D; Cheung AMS; Poon ZY; Yap CS; Goh SE; Guo D; Li H; Bari S; Li S; Lim KH; Hwang WYK
Biol Blood Marrow Transplant; 2018 Oct; 24(10):1971-1980. PubMed ID: 29883796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
